Abstract
Glioblastoma Multiforme (GBM) is the most incident and most aggressive neoplasm of the Central Nervous System (CNS). Temozolamide (TMZ), the drug of choice for the treatment of GBM, has clinical efficacy, but treatment with this drug is associated with the development of resistance in more advanced stages of the disease, in addition to the fact that TMZ has physical and chemical limitatio…